Dr. Henry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-6000
Education & Training
- University of MichiganFellowship, Hematology and Medical Oncology, 2004 - 2007
- Brigham and Women's HospitalResidency, Internal Medicine, 2001 - 2004
- Washington University in St. Louis School of MedicineClass of 2001
- Stanford UniversityPhD, Structural Biology, 1991 - 1996
Certifications & Licensure
- MI State Medical License 2004 - 2026
- UT State Medical License 2016 - 2020
- MA State Medical License 2002 - 2005
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure Start of enrollment: 2007 Aug 01
- A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy Start of enrollment: 2007 Sep 01
- Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain Start of enrollment: 2008 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 150 citationsComparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.Qing Kang, N. Lynn Henry, Costanza Paoletti, Hui Jiang, Pankaj Vats
Clinical Biochemistry. 2016-12-01 - 505 citationsAmerican Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care GuidelineCarolyn D. Runowicz, Corinne R. Leach, N. Lynn Henry, Karen S. Henry, Heather T. Mackey
Journal of Clinical Oncology. 2016-09-19 - 97 citationsSex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.Joseph M Unger, Riha Vaidya, Kathy S Albain, Michael LeBlanc, Lori M Minasian
Journal of Clinical Oncology. 2022-05-01
Press Mentions
- ASCO 2024: Rogel Recap of the 2024 ASCO Annual MeetingJune 19th, 2024
- A Complete Guide to the Five Stages of Breast Cancer and How to Recognize Each StageNovember 8th, 2021
- New Research on Treating Hormone Receptor-Positive Breast Cancer from SABCS 2020January 29th, 2021
- Join now to see all
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: